chrisvoncsefalvay/vaers-outcomes huggingface dataset:
by night bilateral arm heaviness; 8 days out: right forearm weakness paresthesia/pins and needles sensation across neck shoulders extending to upper arms; 7 days after 2nd injection right foot/calf numbness; quadriceps weakness/11 days out left quadriceps weakness; This is spontaneous report from a contactable nurse (patient). A 39-year-old female patient received the second dose of BNT162B2, via an unspecified route of administration in right arm on 05Jan2021 at single dose for COVID-19 immunization. Medical history included hypothyroidism and known allergies: Penicillin. Concomitant medications included levothyroxine sodium (SYNTHROID), colecalciferol (VITAMIN D), and ubidecarenone (COQ10). Patient previously received the first dose of BNT162B2 on 15Dec2020 09:00 in right arm for COVID-19 immunization. 7 days after 2nd injection right foot/calf numbness quadriceps weakness on 12Jan2021 21:00. 8 days out: right forearm weakness paresthesia on 13Jan2021. 11 days out left quadriceps weakness, by night bilateral arm heaviness on 16Jan2021. 12 days out pins and needles sensation across neck shoulders extending to upper arms on 17Jan2021. Deep tendon reflexes intact throughout. Bladder function intact. Events resulted in: Doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Treatment was not received for these events. Outcome of events was not resolved.  Information about lot/batch number is requested.; Sender's Comments: Based on the information currently provided, the vaccination with BNT162B2 might play a contributory role in triggering the onset of the events. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
Onset of mild bronchitis symptoms which persisted over 6 weeks+ complicated by severe sinus infection, nebulizer, prednisone and 4 weeks antibiotic treatment. Similar symptoms and timeline happened to this person in 2009 both years following Flu Mist administration. I suggest looking for possible connection that prior history of sinus infections ought to preclude Flumist eligibility.
When I looked it up it was the two potassium ingredients in it that I am allergic to; This case was reported by a consumer via call center representative and described the occurrence of allergy to vaccine in a 54-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced allergy to vaccine. On an unknown date, the outcome of the allergy to vaccine was unknown.   It was unknown if the reporter considered the allergy to vaccine to be related to Shingrix.  Additional details were reported as follows: The patient was allergic to the two ingredients of Shingrix vaccine which included potassium dihydrogen phosphate and dipotassium phosphate. The patient had zince allergy, zinc makes red and gives trashy skin. The reporter wanted to know what should do if someone is allergic to some ingredients in Shingles shot.
Pregnant women received a flu vaccine; It was sore and she had a bruise in the spot where she was given the injection for a week; It was sore and she had a bruise in the spot where she was given the injection for a week; This is a spontaneous case, initially received from other non-health professional via Med Communications (reference number: SEQ19-03642) on 01-Oct-2019, concerning 28-year-old pregnant female patient.  The patient's medical history included asthma.   The patient's concomitant medications were not provided.  The patient had no obstetrical history. The patient's last menstrual period date (LMP) was on May-2019 and the estimated date of delivery was reported as 17-Feb-2020.  The patient was unsure in regards to prenatal tests and did not have any performed (as reported).  On 01-Oct-2019, at 20 weeks of gestation, the patient was administered Afluria Quadrivalent [Influenza vaccine, batch number: P100118567, expiry date: 30-Jun-2019; dose: 0.5 ml; route of administration: intramuscular, anatomical location: upper right shoulder] (explicitly coded as Vaccine exposure during pregnancy') for an influenza prophylaxis.  On an unspecified date in Oct-2019, the spot where she was given the injection was sore and she developed bruise.   The outcome of events was resolved after a week.    The case was assessed as non-serious. The reporter did not provide causality assessment to Afluria Quadrivalent.   Follow-up received from other non-health professional on 15-Nov-2019: Classification-Special case with No AE and laboratory test removed, last menstrual period date, anatomical location, route of vaccination for Afluria and new events added. The narrative was amended accordingly.   Company Comment: The patient experienced vaccination site bruising and vaccination site pain after vaccination with the suspect product Afluria Quadrivalent. Reportedly, vaccination occurred during pregnancy at 20 weeks of gestation. Chronology is possible. Vaccine exposure during pregnancy is assessed as not related per company's conventions. Causality between suspect product and events vaccination site bruising and vaccination site pain is assessed as possibly related.; Sender's Comments: The patient experienced vaccination site bruising and vaccination site pain after vaccination with the suspect product Afluria Quadrivalent. Reportedly, vaccination occurred during pregnancy at 20 weeks of gestation. Chronology is possible. Vaccine exposure during pregnancy is assessed as not related per company's conventions. Causality between suspect product and events vaccination site bruising and vaccination site pain is assessed as possibly related.
No adverse event; Administered the second Moderna initial series too early. Instead of doing it at the 1 month or 28 days mark, they gave it at the 19th day mark; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Administered the second Moderna initial series too early. Instead of doing it at the 1 month or 28 days mark, they gave it at the 19th day mark) and NO ADVERSE EVENT (No adverse event) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On 06-Jan-2023, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2023,  after starting , the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Administered the second Moderna initial series too early. Instead of doing it at the 1 month or 28 days mark, they gave it at the 19th day mark). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Administered the second Moderna initial series too early. Instead of doing it at the 1 month or 28 days mark, they gave it at the 19th day mark) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Administered the second Moderna initial series too early. Instead of doing it at the 1 month or 28 days mark, they gave it at the 19th day mark).    It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Caller had a nurse that administered the second Moderna initial series too early. Instead of doing it at the 1 month or 28 days mark, they gave it at the 19th day mark. Caller wanted to know if they need to give the patient another dose.  No patient information other than male and vaccine was given on 06-Jan-2023.  No concomitant medication reported. No treatment medication reported.
I have symptoms of shingles the inflammation of the nerves excessive pain in the lower back and hip left side and back of the neck.
After my second COVID vaccine, I developed a spot that was later diagnosed as psoriasis. In July, 2022 I got COVID and the psoriasis spread very quickly throughout my groin area in an inverse psoriasis pattern. I had never had psoriasis in my life. With the next booster shots -- Moderna on 12/29/21  and Pfizer on 5/10/22, and Pfizer on 10/5/22, the psoriasis spread. When it was finally diagnosed, I tried to treat it with topical corticosteroids and light therapy but it continued to spread until it was a severe case, covering about 75% of my torso, as well as my limbs, bottom, and groin area.
Patient received vaccination, sat in exit area for recommended 15min, and left clinic. Patient then returned to clinic within the same hour of vaccination with complaints of heartburn located in center of chest and back pain. RN assessed patient for 15min reviewing options of calling 911, going to PCP, going to hospital if s/s worsen. Patient expressed fearfulness of medical bills. Patient wanted to go home and agreed to go to ER if s/s worsen. HR 80 RR: 12. No SOB, no nausea, no tightness in throat.
Patient reports excrutiating lower back pain that required her to sit with a heating pad pressed the area. She also has a rash that wraps around the left side of her waist band that is inflammed and itchy. Patient is using BENADRYL CREAM on the affected area. If it doesn't clear up in another day she will go to the doctor.
Presented with weakness; Covid +: Admitted to tele  with Covid infection and subsequently, Covid PNA;  tx with remdesivir, steroids, zinc; no O2 initially, but progressed to requiring minimal O2, was weaned off O2 by time of d/c;
Severe muscle aches, chills, runny nose, headaches, dizziness, and debilitating fatigue for several days
My son got the second dose vaccine on Aug 20th at local pharmacy. Allergic reaction started on the 11th day(aug 31st) after getting Pfizer second dose covid 19 vaccine. Hives all over the body, under the neck, side of the neck, behind ears, Lips swelling , Under the eye swelling.
The night of the vaccine woke up with chills, headache, muscle aches. Following evening I had a fever of 100.5, chills, headache, and fatigue.
Approx. 1 hr. after vax, pt. became nauseated, cold, diaphoretic, clammy, dizzy and also had 1 bout of LBM. Pt. missed almost a week of work. Went to Dr and was later dx'd w/bronchitis.
After administering the vaccine the patient stated she felt a little light headed and sat down on the floor.  Then she slumped side ways into a fetal position and stated she felt like she was going to pass out.  The patient never lost consciousness and rested in the fetal position for about 5 minutes.  Then sat up and had some cracker and Gatorade.  The patient felt better, waited in the waiting room chair for another 5 to 10 minutes then left.
Day of vaccination patient developed significant spit ups and fever, following day many loose stools, three days later lethargy, vomiting and continued watery diarrhea.  Seen in office on 10/30/20 with concern for dehydration. Sent to Emergency room same day (10/30/20), found to be dehydrated, hypoglycemic and with diaper dermatitis.  Received IV fluids and subsequent boluses of IV fluid. Seen by Gastroenterology, temporary change to elemental formula. Remained in hospital until 11/7/20. Improved condition at discharge.
This spontaneous report as received from a pharmacist refers to a 68 years old female patient with no known allergies. The patient was vaccinated SC into back of unspecified arm with 0.65 ml ZOSTAVAX (lot # not reported) on 27-AUG-2012. Concomitant medications included hydroxychloroquine sulfate and low dose prednisone. In August 2012 the patient experienced adverse reaction. The patient came to the pharmacy on 29-AUG-2012 with a large red bump, size of a plum, warm to touch, at the injection site of unspecified arm. No treatment was given. No laboratory test was done. At the time of reporting, the patient had not recovered for the events. Additional information has been requested.
Flu Mist applied at 1425, client reported to have nose bleed at 1600, which resolved shortly after. No other symptoms or complications observed or reported. At this time no treatment required.
Transverse myelitis 3 weeks after H1N1 vaccine. 2 days severe back pain followed by LE asymmetric weakness and suspended sensory level. Markedly better after steroids.
approximately 5 hours after vaccine the patient developed chills, body aches, cough, head pressure, and the sensation of feeling flushed.
knee pain; This is a spontaneous report from a contactable physician (patient).  This 62-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot # EK5730), via an unspecified route of administration, on 20Dec2020 at 07:15 AM at single dose for COVID-19 immunisation. Vaccine location was right arm.  The patient was vaccinated at hospital, age at vaccination was 62-years-old. No other vaccine was received in four or two weeks. Medical history was unknown. Concomitant medications were none. Th patient developed left (L) knee pain (7/10) on 23Dec2020 which has not yet resolved as of 28Dec2020. No treatment was administered for the event.
Teacher was given the vaccine on Friday 3/7/08 at 3:00pm by late Friday night to early Saturday morning teacher awoke not feeling well had a very itchy throat.  By late Saturday early Sunday the right side of her face was red puffy and itchy.  On Monday morning I saw the teacher she told be about the the symptoms/ reaction she had over the weekend.  I observed a red splotch in my opinion a hive on her face under her right eye.  She stated that the splotch itched.  I spoke with her at the end of the day she stated that the swelling was getting better, but she was still very itchy.  I advised her to take some Benadryl once she got home.  I spoke with the teacher again on Tuesday she stated that the Benadryl had helped and the red spot was gone.  I spoke with the health dept. about the possible reaction and they advised against future inoculation.
This case was reported by a other health professional via call center representative and described the occurrence of fever in a patient who received KINRIX (batch number 95ZT7, expiry date October 2015). On an unknown date, the patient received KINRIX. On an unknown date, an unknown time after receiving KINRIX, the patient experienced fever. On an unknown date, the outcome of the fever was not recovered/not resolved. It was unknown if the reporter considered the fever to be related to KINRIX.
Booster shot. Vaccine administered to left deltoid.  About 2 days later noticed swelling and soreness in axilla about size of baseball.  No visible color change appreciated.   No palpable lymph nodes appreciated.
Violently ill 8 hrs after vaccine to 16 hrs after vaccine. Never been so sick in "my" life.; Vomiting; diarrhea; fever; chills; aches; headache; cramping; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8735) via an unspecified route of administration in the arm left on 15Apr2021 at 08:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient's medical history were reported as none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient did not receive any medications within two weeks of vaccination. On 15Apr2021 at 16:00, 8 hours after vaccine the patient experienced violently ill to 16 hours after vaccine. The patient was never been so sick in her life. The patient also experienced vomiting, diarrhea, fever, chills, aches, headache and cramping. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event violently ill was recovered on 16Apr2021, while the clinical outcome of the events vomiting, diarrhea, fever, chills, aches, headache and cramping was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Pain in the right side of stomach; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN UPPER (Pain in the right side of stomach) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, the patient experienced ABDOMINAL PAIN UPPER (Pain in the right side of stomach). At the time of the report, ABDOMINAL PAIN UPPER (Pain in the right side of stomach) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications are reported. No treatment information were reported.
Red, itchy, swollen arm in area of injection; approximately 2 inch by 3 inch area.  Resolved gradually over 2 - 3 days.
Patient received first dose of Pfizer covid-19 vaccine on 4/9/2021 at 1800 with her mother in attendance  after consent was acquired.  At 1805 patient began to feel hot and nauseous. The patient thought she was going to vomit, so she left her chair in the waiting area to head to the restroom at the back of the store.  at 1807,  Upon rising the patient became weak in the knees and began to collapse.  The patient's mother initially supported the patient and I was called to assist the patient to the floor. The patient was very pale in appearance as she was assisted gently to the floor, avoiding any injury.  EMS was called shortly after the event around 1810. The patient remained conscious however was a bit disoriented initially while lying on the floor.  The patient recovered quickly, however remained nauseous and complained of feeling hot. Upon questioning the patient, she had not eaten since lunch at school at 1300. The patient was given a cold water and a sprite, of which she had a couple of drinks out of each. The patient was relocated back into a chair at 1815 as she was feeling much better. EMS arrived at 1821. EMS performed a general assessment and a blood pressure check resulting in 130/80. The patient's mother dismissed any further treatment from EMS.  EMS exited the building at 1827.  The patient and mother waited in the store for a while longer.  Both patient and mother exited on their own, denying escort from associates at 1840.
Tiredness; Weakness; Do not feel good; I am losing my voice; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 04Mar2021 (Lot number: EN6198) at the age of 66 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Arthritis" (unspecified if ongoing); "Fibromyalgia" (unspecified if ongoing); "Osteoarthritis" (unspecified if ongoing); "Osteopenia" (unspecified if ongoing); "Degenerative disc disease" (unspecified if ongoing); "Scoliosis", start date: 2011 (unspecified if ongoing); "irritable bowel syndrome", start date: 2011 (unspecified if ongoing); "GERD", start date: 2011 (unspecified if ongoing). Concomitant medication(s) included: GABAPENTIN. Vaccination history included: Bnt162b2 (LOT# of First shot: E19269), administration date: 10Feb2021, when the patient was 66 years old, for COVID-19 IMMUNISATION. The following information was reported: APHONIA (non-serious) with onset Mar2021, outcome "unknown", described as "I am losing my voice"; FATIGUE (non-serious) with onset 04Mar2021, outcome "unknown", described as "Tiredness"; ASTHENIA (non-serious) with onset 04Mar2021, outcome "unknown", described as "Weakness"; MALAISE (non-serious) with onset Mar2021, outcome "unknown", described as "Do not feel good".  Additional Information: It was reported that NDC number, UPC number and Expiry date of COVID-vaccine was Unknown. Patient took COVID vaccine as a preventive measure of COVID.  No follow-up attempts are possible. No further information is expected.
pt recv vax 18SEP97 & on 27SEP97 awoke unable to stand w/o support;pt seen @ hosp & adm;pt evaluated for a head injury sustained 2 days a/which was considered a poss cause of ataxia;CT scan negative as were blood results;
Wife calling to report patient being sick for one week, not eating, has cough & diarrhea.  Reports to Emergency room and is admitted to hospital.
This case was reported by a healthcare professional and described the occurrence of intussusception in a 2-month-old female subject who was vaccinated with ROTARIX (GlaxoSmithKline). There were no reported concomitant medications or relevant medical history. The subject had not experienced adverse events following previous vaccinations. Concurrent vaccination included DAPTACEL (non-gsk) (Sanofi) given on 8 July 2009; PREVNAR (non-gsk) (Wyeth Labs) given on 8 July 2009; IPOL (non-gsk) (Sanofi) given on 8 July 2009. On 8 July 2009 the subject received 1st dose of ROTARIX (1 ml; oral). The lot number was reported as A41OA733A. On 15 July 2009, 7 days after vaccination with ROTARIX, the subject experienced intussusception and "severe" vomiting. The subject was hospitalised and the healthcare professional considered the events were clinically significant (or requiring intervention). At the time of reporting the events were improved. The healthcare professional considered the events were probably related to vaccination with ROTARIX.  10/2/09 Hospital records, DC summary, received DOS 7/16/09 to 7/17/09. Assessment: Intussusception. Presented to ER with 2 days of increased vomiting, fussiness, and decreased stooling, no wet diapers. Fever, respirations and heart rate elevated. Rash below chin. Abdomen rigid. Symptoms resolved with air enema. Some ascites.    ICD-9 Codes: 560.0 Intussusception, 276.51 Dehydration. Follow-up information received on 21 August 2009 indicated that the events began on 15 July 2009 and resolving by the following day, 16 July 2009. The subject received an enema for treatment and symptoms resolved. In the reporter's opinion, the events were probably related to treatment with ROTARIX. The child did not receive bowel resection.
Pt experience syncope post administration. Pt had history of this a few years ago but did not experience this with his covid vaccines. Pt also watched the act of the needle entering his fathers skin, which seemed to precipitate the syncope. Pt was eated and lost conciousness for 2 to 3 seconds. Pt remained seated and was uninjured. Pt recovered well after drinking some water, and alcohol swabs applied to the forhead by his father.  Pt remained  seated in the vaccination area for 20 minutes and was driven home by his father.
This spontaneous report as received from an certified Medical Assistant refers to a 19 years old female patient who was vaccinated with the first 0.5 mL intramuscular dose of GARDASIL on 06-AUG-2007 (lot #0927U, exp 17-MAR-2010) and on 27-OCT-2007 received the second 0.5 mL intramuscular dose of GARDASIL (lot # 2765U, exp 11-APR-2010). The patient received the first two doses at another practice which is a pediatric practice. At the site, the patient was seen on 20-JUL-2012, when she received her third 0.5 mL intramuscular dose of GARDASIL (Lot#0131AC, exp 26-OCT-2014). No adverse effect was reported. Additional information has been requested.